EN
Meta title: Selling Tagatose in the US, EU, or Canada: Compliance Files
Meta description: FDA GRAS, EU novel-food rules, labels, warnings, and batch evidence are not interchangeable. Build the right tagatose compliance file for each market.
The supplier sends a U.S. GRAS reference. The brand plans to sell in Europe. The importer asks whether the same document covers Canada. The answer is not “yes, because tagatose is safe.”
Regulatory status, permitted use, ingredient name, nutrition panel, warning language, evidence, and importer responsibilities are jurisdiction-specific. A safety notice or company dossier can be valuable while still failing to answer the exact market-access question.
For tagatose buyers, the professional move is to build a market-specific file before the purchase order, label artwork, and finished-product claim are locked.
Start with the RainwoodBio tagatose product context, then ask the supplier for documents that match the exact country, product category, serving, and form.
A U.S. GRAS notice is not an FDA certificate
FDA’s GRAS program explains that a substance may be considered generally recognized as safe under the conditions of intended use, and the agency’s GRAS notice inventory records agency responses. [FDA GRN 78](https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?id=78&set=grasnotices) lists D-tagatose and records an FDA “no questions” response for the described uses.
That is useful evidence about the notice and its intended conditions. It is not an FDA certification of every supplier’s tagatose, every manufacturing route, every dosage, or every finished product. The buyer still needs to confirm:
- the exact substance and form;
- the notifier and manufacturing route;
- intended food uses and use levels;
- current specifications;
- finished-product label treatment;
- importer and manufacturer responsibilities;
- claim wording and substantiation.
FDA’s 2023 update also states that D-tagatose must be declared as an added sugar on the Nutrition Facts label and discusses a specific enforcement-discretion approach to calorie contribution. [FDA’s D-tagatose labeling update](https://www.fda.gov/food/hfp-constituent-updates/fda-issues-supplemental-response-labeling-d-tagatose-nutrition-facts-label) should be reviewed with the actual finished formula.
Read the tagatose claim and label review before copying a supplier brochure into U.S. artwork.
The EU file has its own entry and conditions
The EU Union list and its implementing regulations govern authorised novel foods and their conditions of use. The D-tagatose entry in Regulation (EU) 2017/2470 identifies the novel food as “D-Tagatose,” lists specifications such as dry-basis assay and loss on drying, and includes a warning condition for products above 15 g per serving and beverages above 1% as consumed. [The EUR-Lex entry](https://eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX%3A32017R2470) should be read in the current consolidated context.
The buyer must still check whether the proposed ingredient is covered by the relevant entry, whether the production route and specifications match, what category the finished product falls into, and what local language and label rules apply. An older or different route may require a separate equivalence or authorisation analysis.
Do not write “EU approved” as a general marketing phrase unless the exact product, route, conditions, and legal basis have been checked.
Canada needs a separate market review
A U.S. GRAS notice or EU novel-food entry does not automatically answer Canadian food, natural health product, or supplement requirements. Product category, ingredient use, label, claims, and importer obligations must be reviewed under the applicable Canadian framework.
Ask the supplier to provide a dossier that can be evaluated, not a promise that “the ingredient is accepted worldwide.” The buyer may need:
- identity and specification;
- manufacturing and source description;
- safety and toxicology information;
- intended use and intake estimate;
- contaminant and microbiological controls;
- allergen statement;
- label and claim proposal;
- certificate and lot documentation.
Use the target-market compliance checklist to turn the regulatory question into an evidence request.
One raw material, three different document decisions
| File element | United States | European Union | Canada |
|---|---|---|---|
| Core status question | GRAS/intended use | Novel-food entry/conditions | Applicable food or supplement pathway |
| Ingredient name | Finished-label rules | “D-Tagatose” entry condition | Canadian label requirements |
| Nutrition | Added-sugar and calorie treatment | Local nutrition rules | Canadian nutrition rules |
| Warning | Check product/category rules | Above stated serving/beverage thresholds | Confirm applicable warning rules |
| Claims | Substantiation and FDA rules | EU claim framework | Canadian claim framework |
| Batch evidence | COA and traceability | Specification and traceability | Importer and product dossier |
The table is not a legal opinion. It is a procurement reminder that one PDF cannot answer all three columns.
The production route can matter to the file
D-tagatose has been produced from different feedstocks and through different enzymatic or chemical routes. FDA’s GRAS Notice 977 discusses a novel enzymatic cascade and compares it with previous methods, including downstream purification and specification considerations. [The notice](https://www.fda.gov/media/155246/download) shows why the production method can be relevant to identity, allergen, impurity, and equivalence questions.
When a supplier changes feedstock, enzyme system, purification, site, or specification, ask whether the market file and finished-product evidence remain valid. “Same ingredient name” is not a complete change-control assessment.
The document package buyers should request
For every target market, request a controlled folder containing:
1. Exact ingredient identity, form, CAS, and synonyms.
2. Current specification and revision history.
3. Manufacturer and production-site information.
4. Feedstock and process description at the required level.
5. Representative and lot-specific COAs.
6. Identity, assay, related-sugar, moisture, heavy-metal, and microbiological methods.
7. Allergen, GMO, solvent, and processing-aid statements where relevant.
8. Packaging, storage, transport, and shelf-life information.
9. Intended use, serving, and finished-product formulation.
10. Proposed label and claim wording.
11. Change-notification and deviation procedures.
12. Market-specific regulatory assessment.
Keep the raw-material file separate from the finished-product file. A valid ingredient document does not prove that the final gummy, beverage, or supplement complies.
How RainwoodBio can support market preparation
RainwoodBio’s public tagatose page and OEM materials are company-published context. They do not establish universal market access, “FDA certification,” or automatic compliance in every country. Ask RainwoodBio to confirm what documents are actually available for the proposed source and finished format.
Useful project outputs include:
- specification and COA gap review;
- target-market document checklist;
- label and serving-size input review;
- sample and finished-product test plan;
- manufacturer/site and traceability confirmation;
- change-control and complaint-response expectations.
Use the market-specific OEM compliance assessment before the label designer finalizes the artwork.
The launch gate
Do not release the first order until:
1. The target country and product category are confirmed.
2. The ingredient route and specification match the market file.
3. The finished serving and label are reviewed under the local rules.
4. Claims are separated from safety and nutrition statements.
5. Lot documents and traceability are ready for import and release.
6. A change in supplier, site, route, or form triggers a documented review.
Request a tagatose target-market compliance-file review. Send RainwoodBio the destination country, product category, formula, serving, label draft, supplier dossier, quantity, and launch schedule so the team can identify missing documents before shipment.
Frequently asked questions
1.Does FDA “no questions” mean the product is FDA approved?
No. It records FDA’s response to a GRAS notice under described conditions. It is not a blanket certificate for every supplier or finished product.
2.Can the EU warning be ignored if the U.S. label has no warning?
No. The finished product must be reviewed under the destination market. The EU D-tagatose entry includes specific warning conditions that may be triggered by serving or beverage concentration.
3.Can one global COA cover every country?
A COA can support multiple markets, but each market may require different specifications, labels, claims, or documents. Confirm the exact gap rather than assuming global acceptance.
References
- FDA GRAS Notice 78, D-tagatose: https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?id=78&set=grasnotices
- FDA GRAS Notice 977, D-tagatose: https://www.fda.gov/media/155246/download
- FDA D-tagatose Nutrition Facts update: https://www.fda.gov/food/hfp-constituent-updates/fda-issues-supplemental-response-labeling-d-tagatose-nutrition-facts-label
- EU Regulation 2017/2470: https://eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX:32017R2470
- RainwoodBio OEM service: https://www.rainwoodbio.com/oem
This article is for international B2B procurement and educational purposes. Regulatory status, safety, labeling, claims, certificates, and import requirements must be confirmed by qualified professionals for the exact ingredient, finished product, and destination market.